Fortress Biotech Inc
Fortress Biotech Inc (FBIO) Implied Volatility Current
FBIO's 30 day implied volatility is 169.16%, with an IV Rank of 53.17%. This is an average IV Rank versus the past year, meaning Fortress Biotech Inc options are fairly priced and currently offer no clear edge to buyers or sellers. FBIO's 30 day historical volatility sits at 54.85%, which means implied volatility is running 114.31 points above historical volatility, as of Nov 13, 2026.
Read more
Tracking FBIO implied volatility helps you spot when Fortress Biotech Inc options are historically cheap or expensive, and where the best trades are hiding. When FBIO IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor FBIO implied volatility current levels in real time and filter for high probability trades.
Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking FBIO IV rank helps you see whether FBIO's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children.
Implied Volatility
IV is slightly elevated. Premiums are richer, leaning toward sellers.
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →